Zacks Investment Research



| Corbus Pharmact |(CRBP-NASDAQ) |

|Current Recommendation |Buy |

|Prior Recommendation |N/A |

|Date of Last Change |01/06/2015 |

| | |

|Current Price (11/12/15) |$1.71 |

|Six- Month Target Price | |

OUTLOOK

|Analyst must write |

SUMMARY DATA

|52-Week High |$4.15 |

|52-Week Low |$0.05 |

|One-Year Return (%) |N/A |

|Beta |N/A |

|Average Daily Volume (sh) |297,734 |

| | |

|Shares Outstanding (mil) |38 |

|Market Capitalization ($mil) |$64 |

|Short Interest Ratio (days) |0.42 |

|Institutional Ownership (%) |8 |

|Insider Ownership (%) |13 |

| | |

|Annual Cash Dividend |$0.00 |

|Dividend Yield (%) |0.00 |

| | |

|5-Yr. Historical Growth Rates | |

| Sales (%) |N/A |

| Earnings Per Share (%) |N/A |

| Dividend (%) |N/A |

| | |

|P/E using TTM EPS |N/A |

|P/E using 2015 Estimate |-5.3 |

|P/E using 2016 Estimate |-5.5 |

| | |

|Zacks Rank |N/A |

| | |

|Risk Level |High, |

|Type of Stock |Small-Growth |

|Industry |Med-Drugs |

|Zacks Rank in Industry |N/A |

KEY POINTS

➢ Analyst must write

OVERVIEW

Analyst must write

INDUSTRY OUTLOOK

INDUSTRY OUTLOOK - POSITIVE

Our outlook for the drug-biotech group is positive. There are a number of strong secular growth drivers that still power the pharmaceutical industry-namely, an aging population and an enormous research and development (R&D) effort to bring new, better drugs to market. People are living longer, and many have prescription pharmaceuticals to thank for it. Recent breakthroughs in oncology, neurology, and cardiology offer sizable market opportunities. Biotechnology research is finally starting to deliver. Expanded knowledge of genomics and proteomics is attracting significant attention from some of the industry's larger players. Drug companies are finding ways to reformulate and enhance current products. This is clearly a positive for the group.

We expect further consolidation throughout the industry. Specifically, we see smaller specialty and generic pharmaceutical companies getting together in an attempt to create scale. This should better allow these companies to compete with the large-cap players. In the large-cap space, we are pleased to see rationalization finally starting to take hold. Companies are divesting slower growth divisions or products, and focusing more on R&D. Bloated sales forces and marketing budgets are also being reigned in to streamline costs and improve margins.

Biotechnology should deliver the next wave of pharmaceutical products to the market. This should allow the group to outperform the broader sector. Thanks to favorable tax legislation and low debt levels, large pharmaceutical companies are in excellent position to acquire their smaller biotechnology brethren. We would be buyers of large profitable biotechnology stocks, as well as small-cap biotechnology stocks with promising pipelines. Performance of the large pharmaceutical group has been poor the past five years, but we believe these companies should have a meaningfully better second half of the decade. Most now offer low valuations and significant turnaround potential.

INDUSTRY POSITION

Analyst must write

RECENT NEWS

Analyst must write

VALUATION

Analyst must write

RISKS

➢ Analyst must write.

INSIDER TRADING AND OWNERSHIP

Analyst must write.

PROJECTED INCOME STATEMENT & BALANCE SHEET

HISTORICAL ZACKS RECOMMENDATIONS

[pic][pic]

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research (“Zacks SCR”), a division of Zacks Investment Research (“ZIR”), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, CFA, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESMENT BANKING, REFERRALS, AND FEES FOR SERVICE

Zacks SCR does not provide nor has received compensation for investment banking services on the securities covered in this report. Zacks SCR does not expect to receive compensation for investment banking services on the Small-Cap Universe.  Zacks SCR may seek to provide referrals for a fee to investment banks. Zacks & Co., a separate legal entity from ZIR, is, among others, one of these investment banks. Referrals may include securities and issuers noted in this report. Zacks & Co. may have paid referral fees to Zacks SCR related to some of the securities and issuers noted in this report. From time to time, Zacks SCR pays investment banks, including Zacks & Co., a referral fee for research coverage.

Zacks SCR has received compensation for non-investment banking services on the Small-Cap Universe, and expects to receive additional compensation for non-investment banking services on the Small-Cap Universe, paid by issuers of securities covered by Zacks SCR Analysts. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, equity research, investment management, non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per client basis and are subject to the number of services contracted. Fees typically range between ten thousand and fifty thousand USD per annum.

POLICY DISCLOSURES

Zacks SCR Analysts are restricted from holding or trading securities placed on the ZIR, SCR, or Zacks & Co. restricted list, which may include issuers in the Small-Cap Universe. ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Each Zacks SCR Analyst has full discretion on the rating and price target based on his or her own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for services described above. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but are not guaranteed as to be accurate nor do we purport to be complete. Because of individual objectives, this report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned. 

ZACKS RATING & RECOMMENDATION

ZIR uses the following rating system for the 1210 companies whose securities it covers, including securities covered by Zacks SCR: Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters. Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters. Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution is as follows: Buy/Outperform- 25.4%, Hold/Neutral- 56.2%, Sell/Underperform – 14.6%. Data is as of midnight on the business day immediately prior to this publication.

-----------------------

Month Day, Year

[pic]Small-Cap Research David Bautz, PhD

312-265-xxxx

email@

scr. 10 S. Riverside Plaza, Chicago, IL 60606

ZACKS ESTIMATES

Revenue

(in millions of $)

| |Q1 |Q2 |Q3 |Q4 |Year |

| |(Mar) |(Jun) |(Sep) |(Dec) |(Dec) |

|2013 |0 A |0 A | | | |

|2014 | | | | | |

|2015 | |0 A |0 A | | |

|2016 | | | | | |

Earnings per Share

(EPS is operating earnings before non recurring items)

| |Q1 |Q2 |Q3 |Q4 |Year |

| |(Mar) |(Jun) |(Sep) |(Dec) |(Dec) |

|2013 | | | | | |

|2014 | | | |-$0.06 A |-$0.13 A |

|2015 |-$0.06 A |-$0.10 A |-$0.06 A |-$0.10 E |-$0.32 E |

|2016 | | | | |-$0.31 E |

|Zacks Projected EPS Growth Rate - Next 5 Years % |N/A |

|N/A |N/A |

| Top 5 Public Companies in the industry |

| | | | |

|Ticker |Company |Market Share |Zacks |

|  |  | |Rec |

|TKPYY |Takeda Pharmact |19.27766 |N/A |

|MKGAF |Merck Kgaa |14.91029 |Hold |

|ALPMY |Astellas Pharma |12.82172 |Hold |

|VRX |Valeant Pharma |9.57371 |Buy |

|SHPG |Shire Plc-Adr |6.97693 |Hold |

| Corbus Pharmact |  |

|Income Statement and Balance Sheet |  |

|(Dollars in millions, except EPS data) |  |

|  | | | | | | | | |

| |12/10 |12/11 |12/12 |12/13 |12/14 |12/15E |

|Sales | |N/A |N/A |0 |0 |0 |N/A |

|  |Cost of Goods Sold |N/A |N/A |0 |0 |0 |N/A |

|  |SG&A |N/A |N/A |0 |0 |1 |N/A |

|  |Other operating expenses |N/A |N/A |1 |0 |1 |N/A |

|  |Interest and other |N/A |N/A |0 |0 |0 |N/A |

|Zacks Adjusted Income before NRI |N/A |N/A |N/A |N/A |-3 |-12 |

|Net Income |N/A |N/A |-1 |-1 |-3 |-12 |

|Diluted EPS before NRI |N/A |N/A |N/A |N/A |-0.13 |-0.32 |

|Reported EPS |N/A |N/A |N/A |N/A |-0.13 |-0.32 |

|  | | | | | | |

|Cash & Marketable Securities |N/A |N/A |1 |0 |6 |6 |

|Current Assets |N/A |N/A |1 |0 |7 |7 |

|Current Liabilities |N/A |N/A |0 |1 |1 |1 |

|Long Term Debt |N/A |N/A |0 |0 |0 |0 |

|Shareholder's Equity |N/A |N/A |0 |-1 |6 |-6 |

Industry Comparables

| |Pr Chg |P/E CurrFY |EPS Gr |Price/ |Price/ |Price/ |

| |YTD | |5Yr Est |Book |Sales |CF |

|CORBUS PHARMACT |-42.8 | | |5.7 | | |

| | | | | | | |

|Industry Mean |2.7 |61.5 |16.7 |8.9 |451.4 |36.2 |

|Industry Median |-13.6 |22.5 |15.8 |3.3 |7.8 |13.6 |

|S&P 500 |-0.6 |17.1 | |6.6 |3.6 |16.1 |

| | | | | | | |

|PHARMAXIS LTD |22.1 | | |1.5 | |2.5 |

|QLT INC |-33.4 | | |1.0 | | |

|MINERVA NEUROSC |-12.8 | | |2.1 | | |

|PAIN THERAPEUT |-6.4 | | |2.6 | | |

| | | | | | | |

CRBP: Zacks Company Report - BUY

-----------------------

[pic]

Zacks Investment Research Page 3 scr.

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download